Introduction
Tuberculosis, one of the oldest diseases known, is caused by an infection with the bacterium Mycobacterium tuberculosis. The seriousness of tuberculosis is underlined by the fact that the World Health Organization (WHO, http://www.who.org) in 1993 took the unprecedented step of declaring the disease a global emergency. The WHO estimates that M. tuberculosis currently infects one-third of the world's population, and caused 1.7 million deaths in 2009. The search for new drugs, and the identification of suitable new drug targets, has become even more urgent due to the emergence of drugresistant and multidrug-resistant strains.
Isopentenyl diphosphate (IPP), the precursor of the highly diversified group of essential isoprenoids, 1 is synthesized through the non-mevalonate pathway in plants, protozoa, green algae, and many bacteria, [2] [3] [4] starting from pyruvate and D-glyceraldehyde 3-phosphate. In other eukaryotes as well as archaea, 5 IPP is instead formed through the classical mevalonate pathway, 6 starting from acetyl-CoA. The different routes used for IPP synthesis suggest that all enzymes within the non-mevalonate pathway are potentially interesting targets for new drugs against many pathogens, including M. tuberculosis. Indeed, studies have shown that all the enzymes within this pathway are essential in Bacillus subtilis. 7 In the second step, 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR, also referred to as IspC; EC 1.1.1.267) catalyzes the NADPH-dependent rearrangement and reduction of 1-deoxy-D-xylulose 5-phosphate (DXP) to form 2-C-methyl-D-erythritol 4-phosphate (MEP), a reaction that also requires the presence of a divalent cation such as Mg 2+ , Co 2+ or Mn 2+ . 8 Knockouts of the dxr gene in Escherichia coli are lethal, 9 and the essentiality of the M. tuberculosis dxr gene for growth in vitro has also been demonstrated. The natural antibiotic fosmidomycin ( Figure 1 ) is a known inhibitor of the non-mevalonate pathway in plants and bacteria. 12, 13 The compound has been shown to efficiently inhibit DXRs from E. coli 14 (EcDXR) and the malaria parasite Plasmodium falciparum 11 (PfDXR) , and the activities of various fosmidomycin analogues on these two enzymes seem to be well correlated. 15 Furthermore, fosmidomycin has antibacterial activity on E. coli 10, 14 as well as inhibiting the growth of P. falciparum in cell culture. 11, 16 The acetyl derivative of fosmidomycin, 3-(N-hydroxyacetamido)-1-propylphosphonic acid 2 (FR900098, Figure 1 ), has also been evaluated in many studies, and shown to be twice as active as fosmidomycin against P. falciparum in vitro and in the P. vinckei mouse model.
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A number of clinical studies have demonstrated that fosmidomycin in combination with clindamycin has efficacy and good tolerability in the treatment of P. falciparum malaria. [17] [18] [19] In 2005, Dhiman et al. 20 showed that fosmidomycin inhibits M. tuberculosis DXR (MtDXR) with an IC 50 of 0.31 µM, but has no effect on M. tuberculosis cell growth. The antibacterial activity of fosmidomycin on E. coli has been shown to rely on a cAMP-dependent glycerol-3-phosphate transporter that allows uptake in that organism, 21 but which seems to be lacking in M. tuberculosis. The absence of activity on M. tuberculosis is not due to the presence of exporters or to modification of fosmidomycin inside the cell. 10 Since the lack of uptake of this compound into the mycobacterial cell most likely results from its polar character, it would be of interest to explore analogues of fosmidomycin with modified hydrophobic/hydrophilic properties as potential antimycobacterial drugs, similar to the approach followed in the pursuit of more bioavailable antimalarial agents. These include modifications of the phosphonate group that yield phosphonate prodrugs expected to enhance oral availability. 22, 23 Different acyl group substituents have also been prepared, as well as modifications of the hydroxamate group and of the three-carbon spacer (see, for example, references [24] [25] [26] and other work cited therein).
Although such analogues have not been evaluated on MtDXR activity or in M. tuberculosis whole cell growth assays, the SAR obtained from the published studies can be used as a starting point for the development of MtDXR inhibitors. The conserved nature of the DXR active site suggests that newly synthesized inhibitors may show broad-spectrum activity against a range of pathogens.
No analogues have yet been synthesized that have been shown to be significantly more potent than fosmidomycin or 2 on either EcDXR or PfDXR. Therefore, it was interesting when Haemers et al. 27 showed that several α-aryl-substituted fosmidomycin analogues were more effective than fosmidomycin in inhibiting the malaria parasite's growth. The 3,4-dichlorophenyl-substituted analogue ( Figure 1 ) was the most potent in the series. The authors speculated that the improved in vitro antimalarial activity could be due either to an improved interaction with PfDXR (compared to EcDXR) or to the electronic and lipophilic properties of the substituent, or alternatively that the aromatic ring in the Cα-position facilitated entry into the parasite cells. Recently, it was suggested 25 that the electron withdrawing properties of the 3,4 dichlorophenyl group lower the pK a of the phosphonate group thereby favoring the doubly-ionized form that seems to be beneficial for activity. 28, 29 The improved activity against the parasite prompted us to first resynthesize this compound (9a) and its acetyl derivative (9c), as well as their monoethyl and diethyl phosphonate esters, and to evaluate the activity of the various analogues on
MtDXR and on M. tuberculosis cell growth. In parallel studies, we determined crystal structures of MtDXR in complex with two such analogues, which show some similarities to, but also important differences from, fosmidomycin binding. These structures provided new insights for the design and synthesis of additional novel inhibitors.
RESULTS AND DISCUSSION
Synthesis and biochemical evaluation of 8a, 8b and 9a-9d. We prepared both formyl (9a) and acetyl derivatives (9c) of the Cα-substituted analogues. Furthermore we prepared the monoethyl (9b, 9d) and diethyl phosphonate esters (8a, 8b) of these analogues ( Table 1 ). The compounds could be synthesized as racemic mixtures in good yield according to published procedures 30 and as described below (Scheme 1). The inhibitory capacity of the analogues was evaluated in a spectrophotometric assay, in which the MtDXR-catalyzed NADPH-dependent rearrangement and reduction of DXP to form MEP is monitored at 340 nm (see experimental section). The compounds were also tested for activity against the growth of M. tuberculosis strain H37Rv in a microplate Alamar blue assay. lacked activity (IC 50 > 100 µM). This is consistent with previous findings for EcDXR; molecules with two charges on the phosphonate moiety are most active, while activity falls when one of the charges is removed, and the uncharged molecule is inactive. 29 The reasons for the progressive decrease in activity are probably steric as well as electrostatic; our earlier structural results showed that the phosphonate group interacts with a cluster of MtDXR side chains, and with a number of water molecules that lead out to the solvent continuum. 31 It was encouraging, however, to see that there is room for at least one ethyl group in the MtDXR phosphonate binding site (9b and 9d) that can be used to increase the general lipophilicity of such inhibitors. Because the predicted lipophilicity of these compounds is higher than for fosmidomycin (ClogP fosmidomycin = -1.8 and ClogP 9a = 1.2) and since they are active on the 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 parasite assay, it was anticipated that they could show some activity on M. tuberculosis cell growth.
However, all six compounds had MICs > 32 µg/ml.
MtDXR crystal structures.
Crystallographic studies were initiated in parallel, to reveal the mode of binding of the fosmidomycin analogues to MtDXR, and so act as a framework for the design of more potent analogues with more promising biological properties. All structural investigations to date have shown that DXR exists as a homodimer. Each subunit consists of three domains, an N-terminal NADPH binding domain, a C-terminal α-helical domain and a catalytic domain that also provides much of the dimer interface. DXRs, in general, show structural differences due to rigid-body domain motions combined with the flexibility of an active site flap. We have previously described structures of MtDXR produced under two different crystallization conditions. In our first study, using an enzyme truncated by 20 residues at the C-terminus, 32 both magnesium sulfate and fosmidomycin were present in the crystallization, but only a sulfate ion could be located in the DXP binding site where fosmidomycin binds. After truncating the C-terminus by an additional four residues, we produced new (better and more reproducible) crystals in ammonium sulfate, which allowed us to study the binding of fosmidomycin, NADPH and the manganese ion. 31 all five structures is of good quality, with the exception of the N-terminal His 6 -tag, the first 10 residues, the active site flap of the A subunit (residues A198-A208), and residues A69-A78 in the MtDXR c structures. The density for the cofactor in the MtDXR b -9a-NADPH structure is weaker than we observed in the equivalent fosmidomycin ternary complex (PDB code 2JCZ). 31 In particular, the NADPH in the B subunit is best defined for the phosphate groups and is otherwise poorly defined.
Binding of fosmidomycin analogues.
The two fosmidomycin analogues bind in a very similar manner in the DXP/MEP site of the A chain, both in the presence and absence of NADPH ( Figure 2 (MtDXR b -9a-NADPH) are shown in Figure 3 . As for the inhibition studies, a racemic mixture was used in the crystallographic work. Our crystallographic results indicate that 9a and 9c bind primarily, if not exclusively, as the S-enantiomers (see supplemental data). The phosphonate group of each makes interactions with the backbone nitrogen of Ser177, as well as the side chains of Ser177, Ser213 (in one of its two possible conformations), Asn218, Lys219 and several waters. The hydroxamate group is bound in a very similar manner in each of the analogue complexes, coordinating the manganese ion and overlapping with two of the three metal-bound waters in apo-MtDXR b ; interactions between the terminal oxygen and the side chains of Asp151 and Ser152 are also present. A sixth metal-coordinating group, the third water in apo-MtDXR b , is absent in the complexes due to lack of space. The dichlorophenyl ring shows some variability, including a 180° flip; electron density is weakest for the ring, which may arise from heterogeneity concerning the ring flip, from some small population of bound R-enantiomer, or both. Finally, the fosmidomycin propyl backbone atoms assume a very similar conformation in the three analogue structures.
Unexpectedly, the backbone conformation seen for the α-aryl fosmidomycin analogues differs from that observed for fosmidomycin itself, with two of the three torsion angles, adopting different rotamers ( Figure 2D ). Interestingly, our modeling of the R-enantiomers of 9a and 9c suggests that they would adopt backbone conformations more similar to fosmidomycin when binding to the active site, because of steric constraints. However, until the optically pure enantiomers of 9a and 9c have been prepared and evaluated it is not possible to say if both enantiomers are active or if the binding is stereoselective.
Large changes have been described previously in a particular loop near the active site of both MtDXR 31 and EcDXR. 33 In the present case, the most dramatic change is the fact that this flap, containing Trp203 Structure-based design to investigate the hydrated cavity. One obvious conclusion from the structural work is that the opening of the active-site flap in the analogue-bound structures creates a large 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 solvent-exposed region that could be explored using Cα-substitutions other than the 3,4-dichlorophenyl ring seen in our complex structures. Indeed, Haemers et al. 27 showed that analogues of 2 representing a variety of para and meta substitutions of the phenyl ring could be accommodated by EcDXR with only modest differences in potency. We have previously described a hydrated cavity close to the DXP/MEPbinding site that is lined with the side chains of conserved amino acids. 31 It became apparent that this cavity could be reached from the ortho position of the 3,4-dichlorophenyl ring of 9a ( Figure 4A ), which we attempted to exploit to optimize the binding of this structural class. For synthetic reasons, we prepared derivatives based on the Cα-substituted phenyl ring instead of the 3,4-dichlorophenyl moiety.
Furthermore, we decided to prepare the acetyl instead of the formyl analogues, since these are generally more stable and have similar potency (e.g. comparing pairs of compounds in Table 1 ). PyMOL. 37 The protein surface is shown in blue, compound 9a in purple, the four waters in the hydrated cavity in red, Mn 2+ in black, and the nicotinamide moiety of the NADPH cofactor in green. DXR is known to be a challenging protein to use in structure-based drug design, primarily because of the flexible flap and the strong substrate/inhibitor-metal interactions. 24 As a control experiment, we redocked fosmidomycin to the MtDXR b -fosmidomycin-NADPH structure 31 (PDB entry 2JCZ), and 9a
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to the MtDXR b -9a-NADPH structure, with NADPH and the manganese ion included in the complex, as described in the Methods section. Each inhibitor was randomly perturbed, and after redocking, the RMSDs between the best-scored docked pose and the X-ray structure were 0.47 Å and 0.33 Å, respectively (heavy atoms superimposed). Encouraged by these results, we proceeded with this protocol in docking studies to evaluate an expanded set of potential inhibitors. A total of 441 synthetically feasible compounds were built based on the assumption that ortho substituents could be introduced using a Suzuki reaction starting from boronic acids and the phenyl halide. These were docked to the MtDXR b -9a-NADPH crystal structure in order to evaluate their fit to the substrate-binding pocket of the enzyme. Two compounds, one incorporating a pyridine substituent (9h) and one a thiophene substituent (9j), were chosen from these studies (see Table 2 ). The top-scoring docking pose of both these compounds places the ortho substituent in the hydrated cavity with the backbone adopting almost exactly the same conformations as in the MtDXR b -9a-NADPH crystal structure. However, the phenyl ring was slightly reoriented. The nitrogen in the pyridine substituent was able to hydrogen bond to His248. The ortho-bromo substituted compound 9f, which can be readily accessible from the common intermediate 7d, was also evaluated.
Additionally, compounds incorporating a nitrile (9g), hydroxymethyl (9k) and hydroxyethyl group (9n) were suggested, with the intent of introducing a more hydrophilic group in the pocket that could displace one of the water molecules while keeping the hydrogen bonding pattern intact. Docking of these compounds into the MtDXR b X-ray structure, after removal of the four water molecules, indicated that at least 9n could participate in the water-mediated hydrogen bonding interaction with His248
( Figure 4B ). The methoxymethyl 9m and methyl 9l compounds were intermediates in the synthetic route leading up to the other compounds, and were also evaluated. For comparison we also prepared the non-substituted Cα-phenyl analogue (9o). This compound was previously shown to have an IC 50 of 0.3 µM on EcDXR. 27 Finally, we prepared the cyclic phosphonate ester (12), a rigidified analogue that was reachable using the same synthetic route that led to 9k. Scheme 1. Synthesis of α-aryl substituted fosmidomycin analogues 9a-9j. Synthesis of compounds 8a, 8b, 9a-o and 12. The synthesis of the desired compounds is outlined in Scheme 1 and Scheme 2 (see also supporting information). The route is a modification of a previously reported method. 27 It starts with the synthesis of α,β-unsaturated aldehydes 4a and 4b, prepared from boronic acids 3a and 3b and acrolein in an oxidative Heck reaction (Scheme 1). 38 Aldehydes 4c and 4d
were instead obtained from aryl halides and acrolein diethyl acetal using a palladium(0)-catalyzed Mizoroki-Heck reaction (Scheme 2). 39,40 1,4-Addition of triethyl phosphite to compounds 4a-d in the presence of phenol resulted in formation of the acetal intermediates which were then hydrolysed to aldehydes 5a-d. Next compound 5b was reacted with 3-pyridine boronic acid and 2-thiophene boronic acid in a microwave-assisted Suzuki coupling. 41 Using the Pd(Pt-Bu 3 ) 2 catalyst in the reaction with 3-pyridine boronic acid and the Pd(OAc) 2 /[(t-Bu 3 )HP]BF 4 combination in the reaction with 2-thiophene boronic acid, compounds 5e and 5f were obtained in satisfactory yields (35% and 41%, respectively).
The bromine 7d was also used to prepare the corresponding nitrile derivative 7e via a direct Pdcatalyzed microwave-assisted transformation using Zn(CN) 2 . 42 In the reaction with Obenzylhydroxylamine and the subsequent reduction with sodium cyanoborohydride and hydrochloric acid, aldehydes 5a-f were transformed into benzyloxyamines 6a-f, which were then formylated (7a, 7c)
or acetylated (7b, 7d-i). In order to obtain hydroxamates 8a-b and 8d-j the O-benzyl protecting group was removed in compounds 7a-i using Pd-catalyzed (10% Pd/C) hydrogenation under atmospheric hydrogen pressure. Depending on the starting material, different conditions were used for this reaction.
To avoid debromination, milder conditions (ice-bath, Na 2 CO 3 , THF) 43 were used for compound 7d, while compound 7g required acidic conditions (2M HCl, EtOH) 44 due to the thiophene substituent.
When compound 7d was subjected to Pd-catalyzed hydrogenation without any acid or base additive, both the O-benzyl group and aryl bromide underwent hydrogenolysis to obtain 8k. The non-symmetric dibenzyl derivative, 7h, furnished two products in the hydrogenation reaction, that is, α-ohydroxymethylphenyl-and α-o-methylphenyl-derivatives (8h and 8i). In the case of 8c the benzyl group was deprotected using 1M BCl 3 . The final step in the synthesis was hydrolysis of the phosphonate esters by bromotrimethylsilane in dichloromethane (DCM). It should be noted that 9e partly undergoes deformylation under aqueous conditions. Interestingly, when compound 8h was reacted with TMSBr, in addition to the ester hydrolysis, we also observed the formation of the o-bromomethyl derivative which was transformed to 9m by reaction with MeOH. 45 We used the same approach to prepare 12. Compound 7h was reacted with TMSBr to give 10, which after treatment with NaH gave the bicyclic compound 11 that after hydrogenation gave 12. Incomplete hydrolysis of esters 8a, 8b and 8f, afforded the mono ethylphosphonate esters 9b, 9d and 9i (Scheme 1). All final compounds were purified by reverse phase HPLC using gradient elution of MeOH or MeCN with 0.05% HCOOH in water. Biochemical evaluation of 9e-9o and 12. The different analogues were evaluated for activity on MtDXR ( Table 2 ). For compounds that had more than 35% inhibition at 100 µM, we determined the IC 50 -values. First of all it is interesting to compare the IC 50´s of 9c and 9o, which shows that the chlorine atoms contribute some 10-fold in potency, comparable to what was found for these compounds on EcDXR. 27 The bromo compound 9e had an IC 50 of 5.6 µM, which indicates that substitution in the ortho position is tolerated by the enzyme. However, the activity of the acetyl analogue (9f) dropped ~40-fold. This is a distinctly larger loss of activity than the 5-fold potency difference seen with the 3,4-dichlorophenyl substituted 9a/9c, while 9d actually has a better IC 50 than 9b (Table 1) . A 5-fold potency difference had also been seen in the EcDXR enzyme assay for the corresponding 4-MeO-phenyl substituted analogues, 27 suggesting that there may be differences in how these compounds are interacting with the enzymes. Modelling the ortho substituted bromo compound 9f based on the structure of the 9c complex introduces close contact clashes of the bromine atom with the OE2 atom of Glu153 or with the phosphonate group of the ligand. If the formidomycin backbone is kept fixed, these contacts can only be relieved by a dihedral rotation of the phenyl ring which eventually produces a clash between the acetyl group and the ring. No such clash would exist in the formyl derivative and would, therefore, explain the observed inhibition data. Based on this reasoning, substitutions at the ortho position are more likely to result in poorer inhibition for the acetyl derivative compared to the equivalent formyl compound. Indeed compounds 9g-9j were only weakly potent, having 20-30% inhibition at 100 µM, showing that these substituents did not improve binding. We then tried to replace one of the waters identified in the hydrated cavity of the X-ray structure with a water-mimicking group.
This strategy has previously been used to increase the binding affinity of ligands, presumably due to a favorable increase in entropy associated with the release of the water molecule into the bulk solvent. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Docking studies, after removal of the enzyme-bound water molecules, show that the hydroxyl group of at least 9n is able to replace one of the water molecules in the hydrated cavity ( Figure 4B ). However, the low activity of this compound (IC 50 = 150 µM) indicates that it cannot effectively compete with the interactions between the water molecule and the enzyme (although 9n is indeed more active than 9k, which has a smaller ortho substitution). A cyclic phosphonate ester (12) was also prepared, but lacked activity. Unfortunately, we were unable to produce crystal structures of these complexes to evaluate the accuracy of our docking and modelling experiments, and to give direct experimental evidence for how the different compounds interact with MtDXR. All compounds (9e-9o and 12) were evaluated for their activity against the M. tuberculosis strain H37Rv and shown to have MIC values > 32 µg/ml. 
Conclusions
Fosmidomycin should serve as an excellent starting point for the development of antitubercular drugs.
Clinical trials conducted with fosmidomycin in combination with clindamycin have produced good results in the treatment of acute uncomplicated malaria, showing that PfDXR is a druggable target. 47, 48 Fosmidomycin is also highly active on MtDXR but unfortunately lacks activity on M. tuberculosis whole cells, probably because of poor uptake. Therefore, one of the main challenges is to prepare modified analogues of fosmidomycin that can cross the mycobacterial cell wall. It has previously been shown that introduction of a 3,4-dichlorophenyl group in the Cα-position relative to the phosphonate group produces analogues that have a higher in vitro antimalarial activity than fosmidomycin. We resynthesized this compound and showed that it was potent on MtDXR (9a, IC 50 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 basis for the design of novel, more potent inhibitors against other pathogens, such as the malaria parasite.
Experimental Section

General information
Chemistry. The microwave reactions were performed in a Smith Synthesizer producing controlled irradiation at 2450 MHz with a power of 0-300 W. The reaction temperature was determined using the built-in on-line IR-sensor. Flash column chromatography was performed on Merck silica gel 60 (40-63 µm). Analytical thin layer chromatography was done using aluminium sheets pre-coated with silica gel 60 F 254 . Analytical RPLC-MS was performed on a Gilson HPLC system with a Finnigan AQA quadrupole mass spectrometer with detection by UV (DAD) using an Onyx Monolithic C18 column (50 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 300 Plus instrument at 121.4 MHz or 162 MHz, and the chemical shifts are referenced to 85% H 3 PO 4 which was used as an external standard. Molecular masses (HR-ESI-MS) were determined on a Micromass Q-Tof2 mass spectrometer equipped with an electrospray ion source. All final products were obtained as racemic mixtures. 3-(3,4-Dichlorophenyl)acrylaldehyde (4a), 3-(2-
acid (9o) were previously reported.
30, 49
Materials. All reagents were purchased from commercial suppliers and used without further purification. Dichloromethane (DCM) and tetrahydrofuran (THF) were distilled under nitrogen immediately before use. For DCM, calcium hydride and for THF, sodium/benzophenone ketyl were used as drying agents.
(E)-3-(2-Bromophenyl)acrylaldehyde (4b) 49 A test tube was charged with Pd(OAc) 2 (0.007 g, 0.031 mmol), 2,9-dimethyl-1,10-phenanthroline (Neocuproine, dmphen) (0.006 g, 0.031 mmol) and acetonitrile (2 mL) and the mixture was stirred for 30 minutes at rt. A 2-5 mL microwave-transparent process vial was charged with acrolein (1 mL, 15.50 mmol), 2-bromophenylboronic acid (0.50 g, 3.10 mmol), p-benzoquinone (0.17 g, 1.55 mmol) and acetonitrile (1 mL). The content of the test tube was added to the process vial, which thereafter was capped and exposed to microwave heating for 30 minutes at 100 ºC. After being cooled to room temperature, solvent was removed, and the mixture was diluted with 0.1M NaOH and extracted with DCM. Organic layers were then dried with anhydrous MgSO 4 , the solvent evaporated and the obtained crude product purified by column chromatography on silica gel (isohexane/ethyl acetate, 4/1) to yield 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 minutes. After this time the solution was cooled to 0 ºC and 37% HCl (2 mL) was slowly added. The mixture was then allowed to warm up to room temperature, and NaBH 3 CN (0.05 g, 0.90 mmol) was added; the resulting mixture was stirred for an additional 2 h. After the reaction was completed (TLC, ethyl acetate/methanol, 95/5), the mixture was basified by the addition of 10% NaOH (pH =12) and extracted with DCM. The combined organic layers were dried, filtered and evaporated. The crude product was purified on a silica gel column (DCM/methanol 99/1) to obtain 6b in quantitative yield.
Compound 6b (0.27 g, 0.60 mmol) dissolved in DCM (2 mL) was added to a prepared solution of formic acid (3 mL) and 1,1´-carbonyldiimidazole (0.49 g, 3.00 mmol) in DCM (5 mL). After 40 hours, 60 mL of water was added, and the mixture was extracted with DCM (2 x 60 mL). The combined organic layers were dried, filtered, and concentrated. The crude product was purified by column chromatography on silica gel (EtOAc) to yield 79% of 7c. NaHCO 3 solution. The mixture was extracted with DCM (2 x 50 mL). The combined organic layers were dried and filtered, then concentrated. The crude product was purified using preparative RP LC-MS system with gradient elution (50 to 100% of acetonitrile in 0.05% aqueous formic acid) to yield 73% 8c. 
3-(N-Hydroxyformamido)-1-(2-bromophenyl)propylphosphonic acid (9e)
To a solution of phosphonate diethyl ester 8c (75 mg, 0.19 mmol) in dry DCM (2 mL) was added TMSBr (0.1 mL, 0.76 mmol) dropwise under N 2 at 10 o C and stirred at room temperature. After 6 h the volatiles were removed under vacuum and the resulting crude product was purified using preparative RP LC-MS system with gradient elution (0 to 20% of acetonitrile in 0.05% aqueous formic acid). This was compared to the velocity of the uninhibited reaction and used to calculate enzyme activity.
Enzyme activities were plotted against the corresponding inhibitor concentration and data points were 
Antimycobacterial activity
The antimycobacterial activity of the compounds was determined using a resazurin dye based assay in a 96-well V-bottomed plate format as described by Marcel et al. 51 Serially diluted compound solution was added to log phase culture of M. tuberculosis H37Rv (ATCC #27294). The growth of the bacteria was monitored over a period of 14 days with spectrophotometric readings at 575 and 610 nm. The growth curve and MIC values were computed using XL-fit (Excel, Microsoft Corp).
Crystallographic work
Crystallization trials were performed at 22 ºC by the hanging-drop vapor-diffusion method. Drop 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 NADPH was refined at 1.96 Å resolution (R-factor 17.4%). A complex with compound 9c at 1.95 Å resolution (R-factor 18.5%) was also obtained.
Docking study
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